Hepatitis C: Signs and Symptoms

When the liver becomes inflamed due to infection, disease, drugs, poisons, or excessive alcohol, it is referred to as hepatitis. Infectious hepatitis commonly includes hepatitis A, B, or C. All of these forms are caused by viral infections.

The liver is a two-lobed organ found in the upper-right part of the torso. It is responsible for many functions and substances within the body,

Read more: Hepatitis C: Signs and Symptoms

Hepatitis occurs when the liver becomes inflamed due to infection, disease, drugs, poisons, or
excessive alcohol. HCV can spread through needle sharing. Testing for HCV is important if a
patient is experiencing any of the symptoms.

Source: medicalnewstoday

Sleep Apnea Triggers Pediatric Fatty Liver Disease Progression

Obstructive sleep apnea and low nighttime oxygen - which results in oxidative stress - may trigger progression of pediatric non-alcoholic fatty liver disease to non-alcoholic steatohepatitis.

Non-alcoholic fatty liver disease (NAFLD) describes the accumulation of fat in the liver of people who drink little or no alcohol. In some individuals with the condition, the accumulated fat causes inflammation and scarring in the liver, resulting in a more serious form of the disease called non-alcoholic steatohepatitis (NASH).

A disease of epidemic proportions, rates of NAFLD are increasing worldwide in both adults and children. NAFLD affects an estimated 30 percent of the population in Western countries and up to 9.6 percent of all children.

Around 38 percent of obese children are affected across the NAFLD spectrum, which includes isolated hepatic steatosis, non-alcoholic steatohepatitis, and cirrhosis.

Read more: Sleep Apnea Triggers Pediatric Fatty Liver Disease Progression

A combination of OSA and low nighttime oxygen triggered NAFLD progression in obese adolescents.

Source: medicalnewstoday

SAQs 3: Gilbert's Syndrome - A 24-year old man with no significant past medical history presents with an episode of mild jaundice.

A 24-year old man with no significant past medical history presents with an episode of mild jaundice. His liver function tests are normal apart from a bilirubin of 45 µmol/L. There is no bilirubinuria. His GP wonders whether this could be due to hemolysis, but you wish to explore an alternative diagnosis of Gilbert's Syndrome.

Answer these questions:

(a) Is this patient likely to have conjugated or unconjugated hyperbilirubinaemia?

(b) State two routinely available biochemistry tests that are of use in the exclusion of hemolysis.

(c) What might be seen on blood microscopy indicating increased erythrocyte turnover secondary to hemolysis?

(d) State two factors that exacerbate the mild hyperbilirubinemia of Gilbert's syndrome.

(e) Describe the genetic cause of Gilbert's syndrome.

(f) Discuss the diagnostic performance of genetic testing for Gilbert's syndrome.

Source: rcpath/biochemistry

Click here for Answers

Viral Hepatitis Has Become a Leading Global Killer

Compared with most other communicable diseases, hepatitis has risen in global importance since the 1990s. It is now a leading cause of death and disability worldwide and kills at least as many people as tuberculosis, HIV/AIDS, or malaria.

This is the main finding of an international study - led by Imperial College London in the United Kingdom and the University of Washington in Seattle - published in The Lancet.

The study - which analyzes data from 1990-2013 on 183 countries - is timely, as the World Health Organization (WHO) launch a major new effort to tackle viral hepatitis.

The findings should prove of "crucial importance to global health policy," note the authors.

Read more: Viral Hepatitis Has Become a Leading Global Killer

At 1.45 million deaths a year, viral hepatitis now ranks among the world'sleading
infectious diseases - such as TB, AIDS/HIV, and malaria.

Source: medicalnewstoday

Non-Alcoholic Fatty Liver Disease: Scientists Identify Trigger and Treatment

Apart from lifestyle changes and weight loss, there are currently no effective or safe treatments for non-alcoholic fatty liver disease. Now, for the first time, researchers find that a protein called cdk4 occurs at higher levels in mouse models and human patients with the disease. Also, when they blocked the protein in mice, using drugs, it significantly reduced development of hepatic steatosis - the first stage of the disease.

The study, by Cincinnati Children's Hospital Medical Center in Ohio, is published in the journal Cell Reports.

Senior author Nikolai Timchenko, a professor in the department of surgery at the University of Cincinnati and head of the Liver Tumor Biology Program at Cincinnati Children's, says:

"This is the first study to show that cdk4 triggers development of NAFLD [non-alcoholic fatty liver disease] and that inhibiting this enzyme can both prevent and reverse the first step of the disease."

Read more: Non-Alcoholic Fatty Liver Disease: Scientists Identify Trigger and Treatment

The researchers found high levels of a protein called cdk4 in people with fatty livers.

Source: medicalnewstoday